What is the 13F Pro Quality Score for STXS?

13F Pro ranks Stereotaxis, Inc. (STXS) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View STXS's current score at https://13fpro.ai/research/STXS (free sign-up required for the full ranking).

Where does 13F Pro source STXS data?

All Stereotaxis, Inc. fundamentals and ownership data come directly from SEC EDGAR. Stereotaxis, Inc. files with the SEC under CIK 1289340. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is STXS in?

Stereotaxis, Inc. (STXS) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is STXS research updated on 13F Pro?

STXS's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Stereotaxis, Inc.(STXS)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →NYSE

Institutional-grade research for retail investors

SEC EDGAR: CIK 1289340 STXS stock profile & AI dashboard →

13F Pro Quality Score

16.6/100

Rank #2,732 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

38.0/100

Profitability

8.9/100

Balance Sheet

4.5/100

Earnings Quality

30.0/100

Free Cash Flow

9.8/100

Institutional Flow

44.1/100

Revenue Scale

7.3/100

Dilution Risk

6.4/100

STXS Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Stereotaxis, Inc. (STXS), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores STXS at 16.6/100 on a 32-signal composite quality model, placing it at rank #2,732 of 2,879 stocks — the bottom half of the AI-ranked universe. Areas of concern include balance sheet strength (4.5) and revenue scale (7.3), which score below median versus the broader universe. Shareholder dilution risk is elevated at 6.4/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), Stereotaxis, Inc. reports quarterly revenue of $6.3M, net income of $-5.9M, free cash flow of $-3.5M. Top institutional holders of STXS by reported 13-F value include DAFNA Capital Management, Lagoda Investment Management, L.P., BlackRock,, based on the most recent SEC filings. STXS trades on the NYSE exchange and files with the SEC under CIK 1289340. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate STXS daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Stereotaxis, Inc. directly from SEC EDGAR. Stereotaxis, Inc.'s 13F Pro composite quality score has ranged between 10 and 25 since 2021, currently 16.6 — a stable long-term trajectory across 28 quarterly and live scoring snapshots.

✦

Fun facts about Stereotaxis, Inc.

Quirks, history, and lore behind STXS — the kind of stuff that makes a stock memorable.

1
The Basics
A small-cap U.S. medical device company · listed on Nasdaq · headquartered in Missouri.
2
The Numbers
Annual revenue in the low tens of millions of dollars — this is not a giant, but its niche is highly specialized and its addressable market is growing.
3
The History
Founded around the turn of the 21st century, the company was built around the idea that robotic precision could make certain delicate heart procedures safer and more accurate.
4
The Secret
Its core technology uses magnetic fields to remotely steer thin catheters through the heart, reducing radiation exposure for doctors and improving navigation in complex cardiac anatomy.
5
The Lore
Its robotic system is installed in electrophysiology labs at hospitals worldwide, where it helps treat arrhythmias — letting physicians guide tools with magnets rather than manual pushing and twisting.
6
The Giveaway
The name is practically a cheat code: combine stereo (think 3-D magnetic orientation) with taxis (Greek for 'arrangement') and you have a company that literally steers catheters with magnets inside beating hearts.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q1 2026

$6.3M

Net Income

Q1 2026

$-5.9M

Free Cash Flow

Q1 2026

$-3.5M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+20.9% YoY

$32.4MFY 2025

FY21 $35.0MFY22 $28.1MFY23 $26.8MFY25 $32.4M

Net Income

-4.5% YoY

$-21.6MFY 2025

FY21 $-10.7MFY22 $-18.3MFY23 $-20.7MFY25 $-21.6M

Operating Income

-1.3% YoY

$-22.1MFY 2025

FY21 $-12.9MFY22 $-18.8MFY23 $-21.8MFY25 $-22.1M

EPS (Diluted)

+7.4% YoY

$-0.25FY 2025

FY21 $-0.16FY22 $-0.26FY23 $-0.27FY25 $-0.25

Total Assets

+24.7% YoY

$52.3MFY 2025

FY21 $61.0MFY22 $53.4MFY23 $41.9MFY25 $52.3M

Total Debt

—FY 2025

FY21 —FY22 —FY23 —FY25 —

Op. Cash Flow

-49.7% YoY

$-13.7MFY 2025

FY21 $-2.9MFY22 $-8.4MFY23 $-9.1MFY25 $-13.7M

Metric	FY 2025	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Revenue	$32.4M +20.9%	$26.8M -4.9%	$28.1M -19.6%	$35.0M +31.5%	$26.6M -7.9%	$28.9M
Net Income	$-21.6M -4.5%	$-20.7M -13.2%	$-18.3M -70.7%	$-10.7M -61.2%	$-6.6M -44.8%	$-4.6M
Operating Income	$-22.1M -1.3%	$-21.8M -16.3%	$-18.8M -45.7%	$-12.9M -92.0%	$-6.7M -39.1%	$-4.8M
EPS (Diluted)	$-0.25 +7.4%	$-0.27 -3.8%	$-0.26 -62.5%	$-0.16 -45.5%	$-0.11 -10.0%	$-0.10
Total Assets	$52.3M +24.7%	$41.9M -21.5%	$53.4M -12.4%	$61.0M +10.0%	$55.5M +27.2%	$43.6M
Total Debt	—	—	—	—	$2.2M	—
Operating Cash Flow	$-13.7M -49.7%	$-9.1M -8.6%	$-8.4M -185.6%	$-2.9M +16.1%	$-3.5M +23.9%	$-4.6M

AI Insight: STXS Financial Trends

Stereotaxis remains unprofitable with flat-to-declining revenue and persistent operating cash burn despite marginal equity rebuilding.

• Revenue volatile between $6M–$9M across 8 quarters; no sustained growth trajectory. Q1 2026 at $6M, lowest since Q4 2024.

• Operating losses consistent at $4M–$8M per quarter. Net income improved slightly to $-4M in Q2 2025 but deteriorated back to $-6M by Q1 2026.

• Operating cash burn persistent ($2M–$4M quarterly). Equity recovered from $1M low in Q2 2025 to $14M in Q1 2026, likely via financing.

⚠ Equity swung $1M→$14M in 12 months with no corresponding operational improvement; suggests dilutive capital raises masking operational weakness.

⚠ Q1 2026 revenue ($6M) is 33% below Q3 2024 peak ($9M); commercialization traction absent despite two years of operating losses.

AI Insight: STXS Ratio Trends

Stereotaxis remains deeply unprofitable with no path to breakeven visible; operating margin deteriorated to -95.1% in Q1 2026 after a brief improvement in Q2 2025.

• Operating margin worsened from -45.2% in Q2 2025 to -95.1% in Q1 2026, reversing six-month recovery attempt.

• Net profit margin similarly collapsed to -93.2% in Q1 2026 from -43.5% in Q2 2025, mirroring operational deterioration.

• Return on assets remains deeply negative at -43.4% in Q1 2026, showing persistent asset-value destruction.

⚠ Q2 2025 showed margin improvement to -45.2% OpMargin; no recurrence in subsequent quarters suggests unsustainable one-off benefit.

⚠ Negative ROE of -163.3% in Q1 2026 indicates shareholder capital continues eroding; no equity return metrics available pre-Q4 2024.

Get alerted when STXS's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Stereotaxis, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of STXS

DAFNA Capital Management LLC
$25.2M13,680,554 sh
Lagoda Investment Management, L.P.
$8.0M4,350,400 sh
BlackRock, Inc.
$7.3M3,956,243 sh
VANGUARD CAPITAL MANAGEMENT LLC
$5.5M2,998,044 sh
Arbiter Partners Capital Management LLC
$5.3M2,883,856 sh
GEODE CAPITAL MANAGEMENT, LLC
$3.1M1,675,408 sh
ESSEX INVESTMENT MANAGEMENT CO LLC
$2.9M1,590,101 sh
Archon Capital Management LLC
$2.3M1,226,044 sh
Warberg Asset Management LLC
$2.0M1,094,123 sh
STATE STREET CORP
$1.8M957,768 sh

Fund	Value	Shares
DAFNA Capital Management LLC	$25.2M	13,680,554
Lagoda Investment Management, L.P.	$8.0M	4,350,400
BlackRock, Inc.	$7.3M	3,956,243
VANGUARD CAPITAL MANAGEMENT LLC	$5.5M	2,998,044
Arbiter Partners Capital Management LLC	$5.3M	2,883,856
GEODE CAPITAL MANAGEMENT, LLC	$3.1M	1,675,408
ESSEX INVESTMENT MANAGEMENT CO LLC	$2.9M	1,590,101
Archon Capital Management LLC	$2.3M	1,226,044
Warberg Asset Management LLC	$2.0M	1,094,123
STATE STREET CORP	$1.8M	957,768

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put STXS on your watchlist

Track score changes the day Stereotaxis, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is STXS a good stock to buy?

13F Pro's AI-powered analysis of Stereotaxis, Inc. (STXS) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for STXS are available on the STXS stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own STXS?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling STXS. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Stereotaxis, Inc.'s investment landscape.